This interaction would suggest that targeting TAMs could be relevant in synergising immune checkpoint‐based immunotherapy in various tumour types, and in the context of endometriosis‐related ovarian cancers, specifically ARID1A‐mutated tumours. This evidence concerns the gene ARID1A and ovarian carcinoma.